Loading
A phase 2 trial of durvalumab and olaparib in lung cancer, run by University of Cologne, now recruiting.
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) is a phase 2, interventional study registered as NCT06419179 by University of Cologne, with a registry enrolment figure of 29 participants, started 2024-10-09 and due to reach its primary completion in 2026-09. Interventions recorded: Durvalumab; Olaparib. Conditions listed: Small Cell Lung Carcinoma. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "* Newly diagnosed, histologically documented advanced or metastatic small-cell lung cancer (UICC stage III which is not amenable to curative radiochemotherapy or stage IV)". Sites: Germany. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca, Small-cell lung cancer and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), AstraZeneca, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.